3d agoGuruFocusBULLISH 56Analyst
Archived explainer. For the current picture see today's ORKA page.
Why Is ORUKA THERAPEUTICS I (ORKA) Stock Up Today?
By the Top Tier Newswire AI Desk · November 10, 2026 at 1:23 PM ET · reviewed against 3 wire stories
ORUKA THERAPEUTICS I (ORKA) is up +5.78% in the latest session. Our newswire has captured 3 stories on ORKA across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Oruka Therapeutics stock rose 5.78% to close at $110.61 on Wednesday. The primary driver for the move was the company’s release of third-quarter 2026 financial results, which included new data from the EVERLAST-B trial.
What Happened
Oruka Therapeutics reported third-quarter 2026 results, disclosing a GAAP EPS of -$0.63. This figure was in line with expectations, though some estimates had projected a loss of -$0.60. The company also provided a corporate update highlighting data from the EVERLAST-B trial. Results showed a 61% PASI 100 response rate and an 86% PASI 90 response rate in the ORKA-001 high-dose group. These figures were described as highly consistent with responses seen in the EVERLAST-A trial.
Following the release, several analysts reaffirmed their positive stances on the stock. BTIG reiterated its rating on the shares and maintained a price target of $151. Guggenheim reiterated a Buy rating with a price target of $200. Wedbush also reiterated an Outperform rating, keeping its price target at $165. The company announced it will participate in upcoming investor conferences.
What The Data Shows
The stock has shown a strong upward trend recently, moving up 8.2% over the last eight sessions from $96.65 to $104.56. On November 10, 2026, the stock printed five fresh 52-week highs and three fresh 52-week lows. Insider activity has been notable over the past 90 days, with 17 sales totaling $24.4 million and no buys. The most recent sale was executed by CEO Lawrence Otto Klein on November 2, 2026. Other recent sales include those by General Counsel Paul T. Quinlan on October 20, 2026, and Chief Medical Officer Joana Goncalves on October 15, 2026.
What To Watch
Investors will monitor the company’s participation in upcoming investor conferences for further updates on its pipeline and commercial strategy.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ORKA by the numbers
Last: $110.61Session: +5.78%7 sessions: +13.04%Coverage: 3 stories / 3 sourcesAI sentiment: 57/100 (mixed)
The headlines behind the move
4d agoBusiness InsiderNEUTRAL 50Earnings
Oruka Therapeutics GAAP EPS of -$0.63 in-line
4d agoGlobeNewswireBULLISH 64Earnings
Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A EVERLAST-A responses...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ORKA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ORKA move explainers: 2026-11-10 · 2026-10-27 · 2026-10-26 · 2026-09-23